Pancreatic cancer trial testing JPI-547 with standard chemo
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether adding JPI-547 to standard chemotherapy (modified FOLFIRINOX or gemcitabine with nab-paclitaxel) is safe and tolerable in people with advanced pancreatic cancer. If it works, it may improve treatment options for cancers that have spread or cannot be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic ductal adenocarcinoma that cannot be removed with surgery or has spread
- You have at least one spot the doctors can measure on scans
- Your general strength is good (ECOG 0 or 1) and you’re expected to live at least 12 weeks
- Your blood counts, kidney, and liver tests are in acceptable ranges (with at most one retest during screening)
- You can provide tumor tissue for study at screening (stored sample or a new biopsy with consent)
- You can sign consent after understanding the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (KN510713) combined with the standard chemotherapy mFOLFIRINOX for people with advanced pancreatic cancer that hasn't had prior chemotherapy. The goal is to see if adding the new drug can improve outcomes.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study looks at two treatment approaches for pancreatic cancer. In the first part, a new drug combo called NALIRIFOX is given as the first treatment. In the second part, researchers test whether a special antibiotic can make a common chemo work better by targeting gut bacteria.
This trial tests a new medicine (IBI363) combined with chemotherapy for people with advanced pancreatic cancer that has grown after their first treatment. The goal is to see if this combination can help shrink or control the cancer longer.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.